*September 2021*
Discussing the case for antibody drug conjugate (ADC) or tyrosine kinase inhibitor TKI for HER2 mutated lung cancer at ESMO 2021:


*September 2021*
Discussing the case for antibody drug conjugate (ADC) or tyrosine kinase inhibitor TKI for HER2 mutated lung cancer at ESMO 2021: